This post was originally published on this site
ZURICH (Reuters) – Novartis has bought gene therapy specialist Arctos Medical to boost its efforts finding treatments for patients with severe vision loss, the Swiss company said on Tuesday.
The acquisition, for an undisclosed amount, underscores Novartis’ commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness, it said.
